共 50 条
- [31] Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy.CANCER RESEARCH, 2021, 81 (13)Chaudhary, Amit K.Shi, JiadongCai, WenyanWang, BoZaman, Mohd S.Huang, CaiLin, JunKan, Steven Z.Zhou, JoeDong, JianboLiu, Yue
- [32] Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 52 (01) : 36 - 47Yao, YuanRen, YananHou, XingguoWang, PeiZhu, JinyuLiu, SongMa, XiaokunLiu, TeliYang, ZhiZhu, HuaLi, Nan
- [33] A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Yap, Timothy A.Papadopoulos, Kyriakos P.LoRusso, PatriciaWong, Deborah J. L.Hu-Lieskovan, SiwenHolz, Josefin-Beate
- [34] A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockadeNature Communications, 12Cecile GeuijenPaul TackenLiang-Chuan WangRinse KloosterPieter Fokko van LooJing ZhouArpita MondalYao-bin LiuArjen KramerThomas CondamineAlla VolginaLinda J. A. HendriksHans van der MaadenEric RoversSteef EngelsFloris FransenRenate den Blanken-SmitVanessa Zondag-van der ZandeAbdul BasmelehWillem BartelinkAshwini KulkarniWilfred MarissenCheng-Yen HuangLeslie HallShane HarveySoyeon KimMarina MartinezShaun O’BrienEdmund MoonSteven AlbeldaChrysi KanellopoulouShaun StewartHoracio NastriAlexander B. H. BakkerPeggy ScherleTon LogtenbergGregory HollisJohn de KruifReid HuberPatrick A. MayesMark Throsby
- [35] Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Pelster, MeredithMarron, Thomas UrbanFriend, Brian D.Fan, AlanYang, JianningSpira, Alexander I.
- [36] Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2017, 23 (18) : 5349 - 5357Tolcher, Anthony W.Sznol, MarioHu-Lieskovan, SiwenPapadopoulos, Kyriakos P.Patnaik, AmitaRasco, Dreww.Di Gravio, DonnaHuang, BoGambhire, DhirajChen, YingThall, Aron D.Pathan, NuzhatSchmidt, Emmett V.Chow, Laura Q. M.
- [37] Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Fu, SiqingHarb, Wael A.Patel, Sapna PradyumanLu, CharlesHalperin, Daniel M.Hsu, Yi HsinShi, NaiyiYamamura, YukoTang, TonyJiang, LynnSu, FushengCohen, Julia WandaSchmidt, Emmett V.Wang, Jieyi
- [38] Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Barve, Minal A.Johanns, Tanner MichaelMettu, Niharika B.Rosen, Seth D.Edenfield, William JefferyGutierrez, MartinGiorlando, AimeSchuetz, Thomas
- [39] A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumorANNALS OF ONCOLOGY, 2024, 35 : S521 - S521Sun, Y.Yi, T.Dang, Q.Zhang, Y.Ni, S.Wu, A.Zhao, X.Wang, Z.Lu, Q.Tian, W.
- [40] A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Barve, Minal A.Tolcher, Anthony W.Carvajal, Richard D.Izar, BenjaminEl-Khoueiry, Anthony B.Hanna, Diana L.Tarhini, Ahmad A.Whitman, Eric D.Bhatia, ShailenderDavar, DiwakarLutzky, JoseTaylor, Matthew H.Tello, MoniqueRosenthal, KatherineDanielyan, AnnaYip, Wai KiSong, JamesChand, DhanGrossman, Joseph Elan